Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16422537 | 0.86 | ACHE (0.49) | FUCA1ACHE | |
| SCHEMBL16775256 | 0.86 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL16759827 | 0.86 | FUCA1 (0.64) | FUCA1SIGMAR1S1PR1S1PR5GBA1 | |
| SCHEMBL23752774 | 0.84 | S1PR1 (0.50) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL23752778 | 0.84 | S1PR1 (0.50) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL23752776 | 0.84 | S1PR1 (0.50) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL30138573 | 0.84 | S1PR1 (0.50) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL30177202 | 0.84 | S1PR1 (0.50) | FUCA1SIGMAR1S1PR1S1PR5ACHE | |
| SCHEMBL23752888 | 0.82 | RORC (0.48) | FUCA1SIGMAR1RORC | |
| SCHEMBL23752892 | 0.82 | RORC (0.48) | FUCA1SIGMAR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0740658-B1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS | ABBOTT GMBH & CO KG (DE) | 2003-07-02 | — | — | EP | disclosed |
| EP-0647231-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1997-08-27 | — | — | EP | disclosed |
| US-5616705-A | N-substituted azabicycloheptane derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-01 | — | — | US | disclosed |
| EP-0646113-B1 | SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS | BASF AG (DE) | 1996-12-18 | — | — | EP | disclosed |
| EP-0740658-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1996-11-06 | — | — | EP | disclosed |
| EP-0646110-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS | BASF AG (DE) | 1996-10-23 | — | — | EP | disclosed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| US-5475105-A | N-substituted azabicycloheptane derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-12 | — | — | US | disclosed |
| US-5473080-A | Substituted azabicycloheptane derivatives, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-05 | — | — | US | disclosed |
| WO-1995015312-A1 | N-SUBSTITUTED AZABICYCLOHEPTANE DERIVATIVES USED, FOR EXAMPLE, AS NEUROLEPTICS | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-08 | — | — | WO | disclosed |
| EP-0647231-A1 | N-SUBSTITUTED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AG (DE) | 1995-04-12 | — | — | EP | disclosed |
| EP-0646110-A1 | N-SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0646113-A1 | SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| WO-1994000431-A1 | N-SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000445-A1 | SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS INTERMEDIATE PRODUCTS | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000458-A1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATES USEFUL AS NEUROLEPTIC AGENTS, ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |